S. Gail Eckhardt Medicine University of Colorado Denver Anschutz Medical Campus Biography Publications Institution JoVE Articles S. Gail Eckhardt has not added a biography. If you are S. Gail Eckhardt and would like to personalize this page please email our Author Liaison for assistance. Publications Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents Frontiers in Oncology. 2016 | Pubmed ID: 27471678 Antitumor Activity of the Aurora a Selective Kinase Inhibitor, Alisertib, Against Preclinical Models of Colorectal Cancer Oncotarget. Jul, 2016 | Pubmed ID: 27385211 The Novel Tankyrase Inhibitor (AZ1366) Enhances Irinotecan Activity in Tumors That Exhibit Elevated Tankyrase and Irinotecan Resistance Oncotarget. May, 2016 | Pubmed ID: 27070088 Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jun, 2016 | Pubmed ID: 26831715 Phase I Trial of Vandetanib in Combination with Gemcitabine and Capecitabine in Patients with Advanced Solid Tumors with an Expanded Cohort in Pancreatic and Biliary Cancers Investigational New Drugs. Apr, 2016 | Pubmed ID: 26715573 The Changing Landscape of Phase I Trials in Oncology Nature Reviews. Clinical Oncology. Feb, 2016 | Pubmed ID: 26552953 An Integrated Bioinformatics Analysis to Dissect Kinase Dependency in Triple Negative Breast Cancer BMC Genomics. 2015 | Pubmed ID: 26681397 Antitumor Activity of a Potent MEK Inhibitor, TAK-733, Against Colorectal Cancer Cell Lines and Patient Derived Xenografts Oncotarget. Oct, 2015 | Pubmed ID: 26439693 Combined Inhibition of MEK and Aurora A Kinase in KRAS/PIK3CA Double-mutant Colorectal Cancer Models Frontiers in Pharmacology. 2015 | Pubmed ID: 26136684 The Changing Landscape of Phase I Trials in Oncology American Society of Clinical Oncology Educational Book / ASCO. American Society of Clinical Oncology. Meeting. 2015 | Pubmed ID: 25993134 P53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer Molecular Cancer Therapeutics. May, 2015 | Pubmed ID: 25758253 Phase I Dose-escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Mar, 2015 | Pubmed ID: 25501576 Antitumor Activity of the MEK Inhibitor TAK-733 Against Melanoma Cell Lines and Patient-derived Tumor Explants Molecular Cancer Therapeutics. Feb, 2015 | Pubmed ID: 25376610 Dual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal Cancer PloS One. 2014 | Pubmed ID: 25401499 Distress Among Caregivers of Phase I Trial Participants: a Cross-sectional Study Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. Dec, 2014 | Pubmed ID: 25120010 Association of Age with Survival in Patients with Metastatic Colorectal Cancer: Analysis from the ARCAD Clinical Trials Program Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Sep, 2014 | Pubmed ID: 25002720 Triple-negative Breast Cancer: Bridging the Gap from Cancer Genomics to Predictive Biomarkers Therapeutic Advances in Medical Oncology. May, 2014 | Pubmed ID: 24790649 Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Mar, 2014 | Pubmed ID: 24493827 Targeting Nuclear Kinases in Cancer: Development of Cell Cycle Kinase Inhibitors Pharmacology & Therapeutics. May, 2014 | Pubmed ID: 24362082 From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development Journal of the National Cancer Institute. Oct, 2013 | Pubmed ID: 24052618 Overcoming IGF1R/IR Resistance Through Inhibition of MEK Signaling in Colorectal Cancer Models Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Nov, 2013 | Pubmed ID: 24045180 AZD1480: a Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors The Oncologist. 2013 | Pubmed ID: 23847256 Accelerated Approval and Breakthrough Therapy Designation: Oncology Drug Development on Speed? Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Aug, 2013 | Pubmed ID: 23833307 Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Aug, 2013 | Pubmed ID: 23757356 Initial Clinical Sensitivity and Acquired Resistance to MET Inhibition in MET-mutated Papillary Renal Cell Carcinoma Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Jun, 2013 | Pubmed ID: 23610116 MERTK Receptor Tyrosine Kinase is a Therapeutic Target in Melanoma The Journal of Clinical Investigation. May, 2013 | Pubmed ID: 23585477 Association of the Epithelial-to-mesenchymal Transition Phenotype with Responsiveness to the P21-activated Kinase Inhibitor, PF-3758309, in Colon Cancer Models Frontiers in Pharmacology. 2013 | Pubmed ID: 23543898 Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in Vitro and in Vivo Models of Colorectal Cancer Frontiers in Pharmacology. 2013 | Pubmed ID: 23524533 Utilization of Quantitative in Vivo Pharmacology Approaches to Assess Combination Effects of Everolimus and Irinotecan in Mouse Xenograft Models of Colorectal Cancer PloS One. 2013 | Pubmed ID: 23520486 Multicenter Phase I Trial of the Mitogen-activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Mar, 2013 | Pubmed ID: 23434733 First-in-human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-mechanism Studies Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Feb, 2013 | Pubmed ID: 23403628 Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jan, 2013 | Pubmed ID: 23136197 Phase Ib Trial of the Oral Angiogenesis Inhibitor Pazopanib Administered Concurrently with Erlotinib Investigational New Drugs. Aug, 2013 | Pubmed ID: 23135778 Dogs Are More Sensitive to Antagonists of Inhibitor of Apoptosis Proteins Than Rats and Humans: a Translational Toxicokinetic/toxicodynamic Analysis Toxicological Sciences : an Official Journal of the Society of Toxicology. Nov, 2012 | Pubmed ID: 22843607 A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-kinase Inhibitor, in Patients with Advanced Solid Tumors Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Aug, 2012 | Pubmed ID: 22693357 ATM and MET Kinases Are Synthetic Lethal with Nongenotoxic Activation of P53 Nature Chemical Biology. Jul, 2012 | Pubmed ID: 22660439 Common PIK3CA Mutants and a Novel 3' UTR Mutation Are Associated with Increased Sensitivity to Saracatinib Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. May, 2012 | Pubmed ID: 22553375 Patient-derived Tumour Xenografts As Models for Oncology Drug Development Nature Reviews. Clinical Oncology. Jun, 2012 | Pubmed ID: 22508028 JAK2 Inhibition for the Treatment of Hematologic and Solid Malignancies Expert Opinion on Investigational Drugs. May, 2012 | Pubmed ID: 22493978 Discovery of a Potent Small-molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152) Journal of Medicinal Chemistry. May, 2012 | Pubmed ID: 22413863 第一阶段研究的 Rigosertib,抑制剂磷脂酰肌醇-3 激酶和 Polo 样激酶 1 通路,结合吉西他滨与固体肿瘤和胰腺癌患者。 Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Feb, 2012 | Pubmed ID: 22338014 Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-mutant Colorectal Cancer Models Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Feb, 2012 | Pubmed ID: 22173548 Documenting the Natural History of Patients with Resected Stage II Adenocarcinoma of the Colon After Random Assignment to Adjuvant Treatment with Edrecolomab or Observation: Results from CALGB 9581 Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Aug, 2011 | Pubmed ID: 21747085 Phase I Dose-escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Mar, 2011 | Pubmed ID: 21220471 Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor, in Patients with Advanced Solid Tumors Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Feb, 2011 | Pubmed ID: 21131552 A Phase I Dose-escalation, Safety and Pharmacokinetic Study of the 2-methoxyestradiol Analog ENMD-1198 Administered Orally to Patients with Advanced Cancer Investigational New Drugs. Apr, 2011 | Pubmed ID: 20084425 The Insulin-like Growth Factor I Receptor/insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Nov, 2010 | Pubmed ID: 20943761 Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras-mutated Colorectal Cancer Molecular Cancer Therapeutics. Dec, 2010 | Pubmed ID: 20923857 Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Oct, 2010 | Pubmed ID: 20810384 Gene Array and Fluorescence in Situ Hybridization Biomarkers of Activity of Saracatinib (AZD0530), a Src Inhibitor, in a Preclinical Model of Colorectal Cancer Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Aug, 2010 | Pubmed ID: 20682712 Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jun, 2010 | Pubmed ID: 20530704 Novel Agents in the Treatment of Metastatic Colorectal Cancer Cancer Journal (Sudbury, Mass.). May-Jun, 2010 | Pubmed ID: 20526106 Phase I Dose-escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients with Advanced Cancer Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Jun, 2010 | Pubmed ID: 20458040 Assessment of the in Vivo Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, Against Primary and Cell Line-derived Human Colorectal Cancer Xenograft Models Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jun, 2010 | Pubmed ID: 20406842 A Phase I Study of Weekly R1507, a Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Apr, 2010 | Pubmed ID: 20371689 The First-in-human Study of the Hydrogen Sulfate (Hyd-sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): a Phase I Open-label Multicenter Trial in Patients with Advanced Cancer Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Mar, 2010 | Pubmed ID: 20179232 A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Feb, 2010 | Pubmed ID: 20145186 Phase I Trial of Bortezomib and Concurrent External Beam Radiation in Patients with Advanced Solid Malignancies International Journal of Radiation Oncology, Biology, Physics. Oct, 2010 | Pubmed ID: 20133082 Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-neutralizing Monoclonal Antibody, in a First-in-human Study of Patients with Advanced Solid Tumors Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jan, 2010 | Pubmed ID: 20068101 Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2 Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Feb, 2010 | Pubmed ID: 20048182 Population Pharmacokinetic Model of PI-88, a Heparanase Inhibitor Cancer Chemotherapy and Pharmacology. Mar, 2010 | Pubmed ID: 19633850 BRCA in Breast Cancer: from Risk Assessment to Therapeutic Prediction Drug News & Perspectives. Dec, 2009 | Pubmed ID: 20140280 Targeting Vascular Endothelial Growth Factor Receptor-1 and -3 with Cediranib (AZD2171): Effects on Migration and Invasion of Gastrointestinal Cancer Cell Lines Molecular Cancer Therapeutics. Sep, 2009 | Pubmed ID: 19755510 Metabolic Characteristics of Imatinib Resistance in Chronic Myeloid Leukaemia Cells British Journal of Pharmacology. Sep, 2009 | Pubmed ID: 19663881 Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Sep, 2009 | Pubmed ID: 19652058 Abnormalities in Glucose Uptake and Metabolism in Imatinib-resistant Human BCR-ABL-positive Cells Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. May, 2009 | Pubmed ID: 19401345 KRAS Mutations and Susceptibility to Cetuximab and Panitumumab in Colorectal Cancer Cancer Journal (Sudbury, Mass.). Mar-Apr, 2009 | Pubmed ID: 19390304 Results of a Phase I Trial of 12 Patients with Locally Advanced Pancreatic Carcinoma Combining Gefitinib, Paclitaxel, and 3-dimensional Conformal Radiation: Report of Toxicity and Evaluation of Circulating K-ras As a Potential Biomarker of Response to Therapy American Journal of Clinical Oncology. Apr, 2009 | Pubmed ID: 19307945 Vorinostat and Bortezomib Exert Synergistic Antiproliferative and Proapoptotic Effects in Colon Cancer Cell Models Molecular Cancer Therapeutics. Feb, 2009 | Pubmed ID: 19174560 Clinical Applications of Metabolomics in Oncology: a Review Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jan, 2009 | Pubmed ID: 19147747 KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Mar, 2009 | Pubmed ID: 19124802 Patient-reported Outcomes As a Component of the Primary Endpoint in a Double-blind, Placebo-controlled Trial in Advanced Pancreatic Cancer Journal of Pain and Symptom Management. Feb, 2009 | Pubmed ID: 18723314 A Phase I Study of Bortezomib, Etoposide and Carboplatin in Patients with Advanced Solid Tumors Refractory to Standard Therapy Investigational New Drugs. Feb, 2009 | Pubmed ID: 18618082 Barriers to Enrollment of Elderly Adults in Early-phase Cancer Clinical Trials Journal of Oncology Practice / American Society of Clinical Oncology. Jul, 2008 | Pubmed ID: 20856765 A Phase I Study of Gefitinib, Capecitabine, and Celecoxib in Patients with Advanced Solid Tumors Molecular Cancer Therapeutics. Dec, 2008 | Pubmed ID: 19074845 Targeted Manipulation of Apoptosis in Cancer Treatment The Lancet. Oncology. Oct, 2008 | Pubmed ID: 18760670 Ligand-based Targeting of Apoptosis in Cancer: the Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor-related Apoptosis-inducing Ligand (rhApo2L/TRAIL) Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Jul, 2008 | Pubmed ID: 18640940 A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jul, 2008 | Pubmed ID: 18579665 Truncation in CCND1 MRNA Alters MiR-16-1 Regulation in Mantle Cell Lymphoma Blood. Aug, 2008 | Pubmed ID: 18483394 Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-molecule Mitogen-activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients with Advanced Cancers Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. May, 2008 | Pubmed ID: 18390968 A Phase I Pharmacological and Biological Study of PI-88 and Docetaxel in Patients with Advanced Malignancies Cancer Chemotherapy and Pharmacology. Dec, 2008 | Pubmed ID: 18320191 A Phase I Safety, Pharmacological, and Biological Study of the Farnesyl Protein Transferase Inhibitor, Lonafarnib (SCH 663366), in Combination with Cisplatin and Gemcitabine in Patients with Advanced Solid Tumors Cancer Chemotherapy and Pharmacology. Sep, 2008 | Pubmed ID: 18058098 抑制对厄洛替尼原发性肺腺癌的早期阶段对雄性小鼠。 Cancer Chemotherapy and Pharmacology. Sep, 2008 | Pubmed ID: 18030469 NMR-based Metabolomics: Translational Application and Treatment of Cancer Current Opinion in Molecular Therapeutics. Dec, 2007 | Pubmed ID: 18041668 Investigation of Two Dosing Schedules of Vandetanib (ZD6474), an Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, in Combination with Irinotecan in a Human Colon Cancer Xenograft Model Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Nov, 2007 | Pubmed ID: 17975157 Phase I Trial of Gefitinib in Combination with Radiation or Chemoradiation for Patients with Locally Advanced Squamous Cell Head and Neck Cancer Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Nov, 2007 | Pubmed ID: 17971583 Phase II Trial of Sunitinib in Patients with Metastatic Colorectal Cancer After Failure of Standard Therapy Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Oct, 2007 | Pubmed ID: 17947727 Capecitabine Plus 3-weekly Irinotecan (XELIRI Regimen) As First-line Chemotherapy for Metastatic Colorectal Cancer: Phase II Trial Results American Journal of Clinical Oncology. Aug, 2007 | Pubmed ID: 17762434 Priorities in Colorectal Cancer Research: Recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Jun, 2007 | Pubmed ID: 17538178 A Physiologically Based Pharmacokinetic Model of Docetaxel Disposition: from Mouse to Man Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. May, 2007 | Pubmed ID: 17473210 A Phase I Pharmacokinetic and Pharmacodynamic Study of S-3304, a Novel Matrix Metalloproteinase Inhibitor, in Patients with Advanced and Refractory Solid Tumors Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Apr, 2007 | Pubmed ID: 17404091 Sunitinib: from Rational Design to Clinical Efficacy Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Mar, 2007 | Pubmed ID: 17327610 Novel Targets in Solid Tumors: MEK Inhibitors Clinical Advances in Hematology & Oncology : H&O. Nov, 2006 | Pubmed ID: 17143253 Dynamic and Modern: Bringing the Ethics of Phase I Trials Up to Date Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Nov, 2006 | Pubmed ID: 17093287 A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Sep, 2006 | Pubmed ID: 17000682 Randomized Phase III Study of Exatecan and Gemcitabine Compared with Gemcitabine Alone in Untreated Advanced Pancreatic Cancer Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Sep, 2006 | Pubmed ID: 16983112 Sequence-dependent Inhibition of Human Colon Cancer Cell Growth and of Prosurvival Pathways by Oxaliplatin in Combination with ZD6474 (Zactima), an Inhibitor of VEGFR and EGFR Tyrosine Kinases Molecular Cancer Therapeutics. Jul, 2006 | Pubmed ID: 16891475 Development and Validation of a Drug Activity Biomarker That Shows Target Inhibition in Cancer Patients Receiving Enzastaurin, a Novel Protein Kinase C-beta Inhibitor Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jun, 2006 | Pubmed ID: 16740765 Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. May, 2006 | Pubmed ID: 16707611 Anti-tumor Activity of the Combination of Cetuximab, an Anti-EGFR Blocking Monoclonal Antibody and ZD6474, an Inhibitor of VEGFR and EGFR Tyrosine Kinases Journal of Cellular Physiology. Aug, 2006 | Pubmed ID: 16688779 Phase I, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered Ad5CMV-p53, an Adenoviral Vector Containing the Wild-type P53 Gene, in Patients with Advanced Cancer Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. May, 2006 | Pubmed ID: 16648505 A Phase II Study of Intravenous Exatecan Administered Daily for 5 Days, Every 3 Weeks to Patients with Biliary Tract Cancers American Journal of Clinical Oncology. Aug, 2005 | Pubmed ID: 16062073 Safety and Pharmacokinetic Study of RPI.4610 (ANGIOZYME), an Anti-VEGFR-1 Ribozyme, in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors Cancer Chemotherapy and Pharmacology. Oct, 2005 | Pubmed ID: 15906031 A Phase I and Pharmacokinetic Study of Exisulind and Docetaxel in Patients with Advanced Solid Tumors Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Nov, 2004 | Pubmed ID: 15534096 Phase II Studies of Modern Drugs Directed Against New Targets: if You Are Fazed, Too, then Resist RECIST Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Nov, 2004 | Pubmed ID: 15483011 Imatinib (STI571)-mediated Changes in Glucose Metabolism in Human Leukemia BCR-ABL-positive Cells Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Oct, 2004 | Pubmed ID: 15475456 A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Oct, 2004 | Pubmed ID: 15475438 A Phase I, Pharmacokinetic, and Biological Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Gemcitabine in Patients with Advanced Malignancies Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Oct, 2003 | Pubmed ID: 14581347 A Phase I and Pharmacokinetic Study of Squalamine, an Aminosterol Angiogenesis Inhibitor Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jul, 2003 | Pubmed ID: 12855619 Analysis of Docetaxel Pharmacokinetics in Humans with the Inclusion of Later Sampling Time-points Afforded by the Use of a Sensitive Tandem LCMS Assay Cancer Chemotherapy and Pharmacology. Aug, 2003 | Pubmed ID: 12759775 New Targets for Cancer Chemotherapy Cancer Chemotherapy and Biological Response Modifiers. 2002 | Pubmed ID: 12703208 A Phase II Study of Irofulven (MGI 114) in Patients with Stage IV Melanoma Investigational New Drugs. Aug, 2002 | Pubmed ID: 12201500 A Phase I and Pharmacokinetic Study of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, Administered on a Daily-times-five Every-three-week Schedule in Patients with Advanced Solid Malignancies Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jul, 2002 | Pubmed ID: 12114416 A Phase I Study of Pivaloyloxymethyl Butyrate, a Prodrug of the Differentiating Agent Butyric Acid, in Patients with Advanced Solid Malignancies Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jul, 2002 | Pubmed ID: 12114414 Angiogenesis Inhibitors in Clinical Development for Lung Cancer Seminars in Oncology. Feb, 2002 | Pubmed ID: 11894016 A Phase I and Pharmacokinetic Study of Ecteinascidin-743 on a Daily X 5 Schedule in Patients with Solid Malignancies Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jan, 2002 | Pubmed ID: 11801542 开发和维护的临床前患者来源的肿瘤异种移植模型为新的抗癌疗法的调查 Stacey Bagby1, Wells A. Messersmith1, Todd M. Pitts1, Anna Capasso1, Marileila Varella-Garcia1, Peter J. Klauck1, Jihye Kim1, Aik-Choon Tan1, S. Gail Eckhardt1, John J. Tentler1, John Arcaroli1 1Medicine, University of Colorado Denver Anschutz Medical Campus JoVE 54393 Pesquisa do câncer
开发和维护的临床前患者来源的肿瘤异种移植模型为新的抗癌疗法的调查 Stacey Bagby1, Wells A. Messersmith1, Todd M. Pitts1, Anna Capasso1, Marileila Varella-Garcia1, Peter J. Klauck1, Jihye Kim1, Aik-Choon Tan1, S. Gail Eckhardt1, John J. Tentler1, John Arcaroli1 1Medicine, University of Colorado Denver Anschutz Medical Campus JoVE 54393 Pesquisa do câncer